Sign In
Buy PRME
$2.92
-0.100 (-3.31%)
At Close: Jul 31, 2026
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
02:57pm, Wednesday, 31'st Jul 2024
While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results.
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
11:00am, Friday, 19'th Jul 2024
While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
09:25am, Friday, 21'st Jun 2024
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade
10:55am, Thursday, 30'th May 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 121% in Prime Medicine, Inc. (PRME). While the effectiveness of this highly sought-after metric is questionable
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names
06:30am, Wednesday, 29'th May 2024
Biotech stocks are not for the faint of heart. It is a sector that can provide life-changing gains or cause an investment to head towards zero.
Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio
04:10am, Saturday, 25'th May 2024
Alphabet manages more than $7 billion in equity investments, including a publicly traded portfolio. Its biggest holding competes with Microsoft's Github.
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
06:27am, Friday, 17'th May 2024
The ARK Innovation ETF (NYSEARCA: ARKK ) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year. One of
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
06:15am, Friday, 17'th May 2024
With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks to buy h
Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?
10:56am, Tuesday, 14'th May 2024
The consensus price target hints at a 133.6% upside potential for Prime Medicine, Inc. (PRME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
08:00am, Monday, 13'th May 2024
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
08:00am, Friday, 10'th May 2024
-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Present
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Gran
What Makes Prime Medicine, Inc. (PRME) a New Buy Stock
01:01pm, Friday, 03'rd May 2024
Prime Medicine, Inc. (PRME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
08:00am, Tuesday, 23'rd Apr 2024
-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on track to enter cl
